TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7887117
Drug: Inverse Sequence
Normalized name: Inversedine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inverse Sequence Induction (ISI) with atracurium 0.6 mg.kg‐1 followed by thiopental 5 mg.kg‐1
Study: 7887117
Drug: Rapid Sequence
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid Sequence Induction (RSI) with succinylcholine (SUX) precurarized with atracurium 0.06 mg.kg‐1 followed by thiopental 5 mg.kg‐1 and succinylcholine 1.5 mg.kg‐1
Study: 2905148
Drug: Oxazepam 15
Normalized name: oxazepam 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxazepam 15 mg (active control)
Study: 2905148
Drug: Propranolol 40
Normalized name: propranolol 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 40 mg and 160 mg
Study: 25758769
Drug: Saxagliptin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saxagliptin (5 or 2.5 mg daily)
Study: 19967572
Drug: Cognitive-behavioural therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioural therapy including biofeedback tools (CBT-B)
Study: 10812259
Drug: morphine, bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: morphine, bolus 150 microg/kg + infusion 1 microg/kg per min and 0.5 microg/kg per min
Study: 10812259
Drug: ketamine, bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: ketamine, bolus 60 microg/kg + infusion 6 microg/kg per min and 3 microg/kg per min
Study: 27494516
Drug: Intra-articular glucocorticoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular glucocorticoid injections (IAGCIs)
Study: 20979824
Drug: Docetaxel 37.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel 37.5 mg/m² on days 1 and 8, oral capecitabine 950 mg/m² twice daily on days 1-14 (Group A)
Study: 20979824
Drug: Docetaxel 75
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 75 mg/m² on days 1, oral capecitabine 950 mg/m² twice daily on days 1-14 (Group B)
Study: 18570597
Drug: Sibutramine 10
Normalized name: sibutramine 10 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibutramine 10 mg plus verapamil sustained release/trandolapril 180/2 mg
Study: 18570597
Drug: Verapamil sustained
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil sustained release/trandolapril 180/2 mg
Study: 12593526
Drug: Beclometasone dipropionate
Normalized name: Beclometasone dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Beclometasone dipropionate (BDP) suspension for nebulization 2,400 microg day(-1) b.i.d. (n = 103)
Study: 12593526
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP) suspension for nebulization 2,000 microg day(-1) b.i.d. (n = 102)
Study: 10578972
Drug: NMP179 monoclonal
Normalized name: factor VIII
DrugBank: Beroctocog alfa (DB14473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NMP179 monoclonal antibody
Study: 8851320
Drug: Regimen A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen A: 6 x 0.5 ml per kg body weight
Study: 8851320
Drug: Regimen B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen B: 0.25 ml per kg body weight at gastric pH < 3
Study: 1654365
Drug: Rotavirus vaccine
Normalized name: rotavirus vaccine
DrugBank: Rotavirus vaccine (DB10276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotavirus vaccine strain M37 (10^5-pfu dose) in adults
Study: 1654365
Drug: Rotavirus vaccine
Normalized name: rotavirus vaccine
DrugBank: Rotavirus vaccine (DB10276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotavirus vaccine strain M37 (10^4-pfu dose) in infants and children
Study: 1654365
Drug: Rotavirus vaccine
Normalized name: rotavirus vaccine
DrugBank: Rotavirus vaccine (DB10276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotavirus vaccine strain M37 (10^5-pfu dose) in infants
Study: 1654365
Drug: Rotavirus vaccine
Normalized name: rotavirus vaccine
DrugBank: Rotavirus vaccine (DB10276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotavirus vaccine strain M37
Study: 28034414
Drug: SMS reminders
Normalized name: Samarium Sm-153
DrugBank: Samarium Sm-153 (DB12905)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SMS reminders regarding adherence to a healthy diet, medication, and smoking cessation
Study: 25882510
Drug: Thrombectomy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombectomy with Solitaire stent retriever and medical therapy (including intravenous alteplase when eligible)
Study: 21446902
Drug: Simvastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (40 mg po qD)
Study: 16221754
Drug: Milk thistle
Normalized name: MILK THISTLE
DrugBank: Milk thistle (DB14375)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk thistle (900 mg daily for 14 days)
Study: 16221754
Drug: Black cohosh
Normalized name: black cohosh
DrugBank: Black cohosh (DB13975)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Black cohosh (40 mg daily for 14 days)
Study: 12656875
Drug: Transmandibular implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transmandibular implant according to Bosker
Study: 12656875
Drug: Augmentation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Augmentation of the mandible followed by four endosseous implants
Study: 12656875
Drug: Insertion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insertion of four short endosseous implants
Study: 12596948
Drug: Topical ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical ciprofloxacin hydrochloride
Study: 12596948
Drug: Topical gentamicin
Normalized name: gentamicin Topical Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical gentamicin sulfate
Study: 8494079
Drug: Imipramine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine treatment after dosage increases or disulfiram
Study: 3095641
Drug: Ceftriaxone 125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 125 mg intramuscular dose
Study: 3095641
Drug: Kanamycin 75
Normalized name: kanamycin 75 mg/2 mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kanamycin 75 mg intramuscular dose plus topical gentamicin for 7 days
Study: 3095641
Drug: Kanamycin 75
Normalized name: kanamycin 75 mg/2 mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kanamycin 75 mg intramuscular dose plus topical tetracycline for 7 days
Study: 3095641
Drug: Kanamycin 75
Normalized name: kanamycin 75 mg/2 mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kanamycin 75 mg intramuscular dose
Study: 30200092
Drug: Thyroid tablet
Normalized name: Thyroid Tablets
DrugBank: Thyroid, porcine (DB09100)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyroid tablet 0.4 mg/kg taken orally once a day for 4 days before surgery
Study: 27348542
Drug: 0.1 mg
Normalized name: biotin 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg triptoreline
Study: 21740277
Drug: Eyeliner adjunct
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eyeliner adjunct to IPL
Study: 21740277
Drug: Color-dye adjunct
Normalized name: amaranth dye
Approvals — FDA: no, EMA: no, PMDA: no
Description: Color-dye adjunct to IPL
Study: 2423337
Drug: beta-sitosteryl beta-D-glucoside
Normalized name: beta-sitosteryl sulfate
Approvals — FDA: no, EMA: no, PMDA: no
Description: beta-sitosteryl beta-D-glucoside (WA184) at a dose of 0.3 mg/day
Study: 29531924
Drug: PGB 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGB 75 mg daily
Study: 29531924
Drug: PGB 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGB 75 mg daily and Met 500 mg daily for 3 months
Study: 23644549
Drug: golimumab 100
Normalized name: golimumab 100 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: golimumab 100 mg every 4 weeks
Study: 23644549
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with baseline CRP levels <1.5 mg/dl
Study: 22575398
Drug: Emergency endoscopic
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emergency endoscopic therapy (EST)
Study: 16723055
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg morphine sulphate orally every 4 h for 24 h
Study: 16723055
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg morphine sulphate orally every 4 h for 24 h
Study: 16723055
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg morphine sulphate orally every 4 h for 16 h (pharmacokinetic study)
Study: 12855090
Drug: Experiential-Cognitive Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experiential-Cognitive Therapy (ECT) - 8 sessions
Study: 12855090
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) - 12 sessions
Study: 9208626
Drug: Methimazole (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methimazole (40 mg/d, tapered to 20 mg/d after two weeks)
Study: 9208626
Drug: Methimazole combined
Normalized name: Methimazole
DrugBank: Methimazole (DB00763)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methimazole combined with Dexamethasone (Dex, 6 mg/d, reduced to 4.5 mg/d on the 5th day and to 2.25 mg/d two weeks after treatment)
Study: 1597229
Drug: Diltiazem (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (90 mg t.i.d.)
Study: 1597229
Drug: Gallopamil (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gallopamil (50 mg t.i.d.)
Study: 6397331
Drug: Flunisolide (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunisolide (2 sprays to each nostril twice daily for 7 weeks)
Study: 6397331
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate (2 sprays to each nostril twice daily for 7 weeks)
Study: 31531996
Drug: Creatine Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine Group (CG) - received creatine plus maltodextrin, 1st week: 20 g/day of creatine plus 20 g/day of maltodextrin and 2nd-4th weeks: 5 g/day of creatine plus 5 g/day of maltodextrin
Study: 31531996
Drug: Placebo Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Group (PG) - received maltodextrin, 1st week: 40 g/day and 2nd-4th weeks: 10 g/day
Study: 17962204
Drug: CapOx (capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: CapOx (capecitabine 1000 mg/m² twice daily on days 1‐14 plus oxaliplatin 130 mg/m² on day 1)
Study: 17962204
Drug: CapGem (capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: CapGem (capecitabine 825 mg/m² twice daily on days 1‐14 plus gemcitabine 1000 mg/m² on days 1 and 8)
Study: 17962204
Drug: mGemOx (gemcitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: mGemOx (gemcitabine 1000 mg/m² on days 1 and 8 plus oxaliplatin 130 mg/m² on day 8)
Study: 16816537
Drug: Procalcitonin alone
Normalized name: Procalcitonin
DrugBank: Procalcitonin (DB14812)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procalcitonin alone or in combination with interleukin-6
Study: 9377610
Drug: Naprelan 1000
Normalized name: Naprelan
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naprelan 1000 mg QD
Study: 24228533
Drug: Integrated treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated treatment of traditional Chinese medicine and Western medicine (TCM-WM)
Study: 23173245
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine treatment
Study: 16553541
Drug: Fluoxetine 40-60
Normalized name: fluoxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 40-60 mg/day
Study: 14977438
Drug: Isoflavone supplement
Normalized name: Soyrel Soy Isoflavone Supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoflavone supplement (90 mg total isoflavones/day)
Study: 1902418
Drug: Mitomycin C
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin C or Adriamycin, administered endovesically
Study: 6124859
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg bupropion p.o.
Study: 17516829
Drug: Low-dose recombinant
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose recombinant IGF-I
Study: 15738542
Drug: docetaxel (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: docetaxel (70 mg/m2 on day 2 or 35 mg/m2 on days 2 and 9 of each 21‐day cycle) and estramustine (280 mg p.o. tid on days 1 through 5 and 8 through 12) plus prednisone (10 mg daily)
Study: 15738542
Drug: mitoxantrone (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: mitoxantrone (12 mg/m2 every 3 weeks) plus prednisone (10 mg daily)
Study: 11943004
Drug: Dual-wave insulin
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual-wave insulin administration (70% as a bolus and 30% as a square-wave over 2 h)
Study: 11943004
Drug: Square-wave insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Square-wave insulin administration (over 2 h)
Study: 11943004
Drug: Single bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single bolus insulin administration
Study: 11943004
Drug: Double bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double bolus insulin administration (two separate boluses of one-half the same total dose)
Study: 2200384
Drug: Control (Stable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (Stable or forced-dose titration sequence)
Study: 7345158
Drug: Men's group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Men's group treatment of erectile dysfunction with communication and dating skills training; 10 sessions over 6 weeks
Study: 7345158
Drug: Men's group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Men's group treatment of erectile dysfunction
Study: 31221944
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg BioCell Collagen supplement taken twice daily
Study: 26369333
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) and static stretching (LLLT+Stretch)
Study: 26369333
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) placebo and static stretching (LLLTPLACEBO+Stretch)
Study: 26369333
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) alone
Study: 24158199
Drug: BNP of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNP of 500 pg/mL or greater
Study: 24158199
Drug: RVEDVI of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: RVEDVI of 140 mL/m or greater
Study: 19640922
Drug: Roxithromycin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxithromycin (300 mg daily for 4 weeks annually)
Study: 12616435
Drug: Lateral-to-medial (L)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lateral-to-medial (L) group
Study: 10979060
Drug: Montelukast plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast plus Loratadine (10 mg Montelukast + 20 mg Loratadine)
Study: 10979060
Drug: Montelukast alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast alone (10 mg)
Study: 8804377
Drug: Liver transplantation,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liver transplantation, resection, or alcohol injection
Study: 1428573
Drug: 5 Fluoro‐Uracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 Fluoro‐Uracil (5FU) - 10 injections
Study: 1428573
Drug: Daunorubicin -
Normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Daunorubicin - 1 subconjunctival preoperative injection
Study: 3549476
Drug: Radiotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy plus intravenous Corynebacterium parvum (C. parvum)
Study: 3549476
Drug: C. parvum
Approvals — FDA: no, EMA: no, PMDA: no
Description: C. parvum therapy
Study: 30197273
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g OM-3CA
Study: 25743238
Drug: Oxygen-ozone (O2-O3)
Normalized name: ozone
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen-ozone (O2-O3) discolysis with steroid and anesthetic
Study: 25743238
Drug: Steroid and
Normalized name: Corticosteroid and/or corticosteroid derivative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid and anesthetic (Control Group)
Study: 23041591
Drug: Cetuximab maintenance
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab maintenance therapy following definitive RT with concomitant cetuximab
Study: 8781791
Drug: Pethidine hydrochloride
Normalized name: Pethidine hydrochloride
DrugBank: Meperidine (DB00454)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pethidine hydrochloride 1 mg/kg
Study: 6143815
Drug: Temazepam 30
Normalized name: temazepam 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temazepam 30 mg with Cimetidine 300 mg every 6 h
Study: 22339483
Drug: Bencycloquidium bromide
Normalized name: Potassium Bromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bencycloquidium bromide (BCQB) 45-450 μg single intranasal doses
Study: 22339483
Drug: Bencycloquidium bromide
Normalized name: Potassium Bromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bencycloquidium bromide (BCQB) 120 μg three times daily for 15 days
Study: 22339483
Drug: Bencycloquidium bromide
Normalized name: Potassium Bromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bencycloquidium bromide (BCQB) 120 μg three times daily for 5 days with a final single dose on day 7
Study: 22339483
Drug: Bencycloquidium bromide
Normalized name: Potassium Bromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bencycloquidium bromide (BCQB) 45, 90, and 180 μg single intranasal doses
Study: 18028196
Drug: Improved mechanical
Normalized name: Improvest
Approvals — FDA: no, EMA: no, PMDA: no
Description: Improved mechanical oral hygiene
Study: 18028196
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of intensive mechanical and antibacterial measures
Study: 16275600
Drug: Naloxone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (10 ng/mL)
Study: 16275600
Drug: Naloxone (0.1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (0.1, 1 ng/mL)
Study: 4091992
Drug: tablet
Normalized name: TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet
Study: 4091992
Drug: retard capsule
Normalized name: diclofenac sodium Extended Release Oral Tablet [Lofensaid Retard]
Approvals — FDA: no, EMA: no, PMDA: no
Description: retard capsule
Study: 29428315
Drug: High testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High testosterone (T) and high antimüllerian hormone (AMH)
Study: 29428315
Drug: Norm testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Norm testosterone (T) and norm antimüllerian hormone (AMH)
Study: 24346596
Drug: DTaP5‐IPV‐Hib‐HepB with
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTaP5‐IPV‐Hib‐HepB with PCV7 administered 1 month later
Study: 20733439
Drug: Desipramine tablets
Normalized name: desipramine Oral Tablet
DrugBank: Desipramine (DB01151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desipramine tablets - placebo cream
Study: 20733439
Drug: Lidocaine cream
Normalized name: Neomycin and Polymyxin B Sulfates and Lidocaine Cream
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine cream - placebo tablet
Study: 20733439
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets - placebo cream
Study: 20733439
Drug: Lidocaine cream
Normalized name: Neomycin and Polymyxin B Sulfates and Lidocaine Cream
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine cream - desipramine tablet
Study: 20733439
Drug: Desipramine tablets
Normalized name: desipramine Oral Tablet
DrugBank: Desipramine (DB01151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desipramine tablets
Study: 7585852
Drug: Intranasal triamcinolone
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal triamcinolone acetonide 220 micrograms plus placebo capsule
Study: 7585852
Drug: Oral loratadine
Normalized name: loratadine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral loratadine 10 mg plus placebo nasal spray
Study: 2258355
Drug: pefloxacin 400
Normalized name: pefloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: pefloxacin 400 mg iv
Study: 2258355
Drug: cefazolin 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: cefazolin 1.0 g iv
Study: 30877937
Drug: Durable-polymer-coated drug-eluting
Normalized name: dicresulene polymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durable-polymer-coated drug-eluting stents (DP-DES)
Study: 26314702
Drug: Midazolam (0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.03 mg/kg of the participant's body mass, to a maximum of 2.5 mg)
Study: 21196617
Drug: Spironolactone 25‐50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone 25‐50 mg/day
Study: 19480864
Drug: Modified acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified acupuncture therapy with needle insertion into multiple loci to elicit local twitch responses at acupuncture points Wai‐guan and Qu‐chi.
Study: 16979835
Drug: Total mesorectal
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total mesorectal excision (TME) and intraoperative electron‐beam radiation therapy (IOERT) with preoperative or postoperative chemoradiation (CRT)
Study: 15283927
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg per day tibolone (OD, n = 18)
Study: 15283927
Drug: daily combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: daily combined 0.625 mg of conjugated estrogens 2.5 mg-1 of medroxy progesterone acetate pill (EP, n = 20)
Study: 15283927
Drug: Vitamin pill
Normalized name: vitamin A Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin pill (C, n= 20)
Study: 11275387
Drug: Group cognitive-behavioral
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group cognitive-behavioral therapy (12-week trial)